Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Individualization of leflunomide dosing in rheumatoid arthritis patients
Author: Hopkins, A.
O'Doherty, C.
Foster, D.
Upton, R.
Proudman, S.
Wiese, M.
Citation: Personalized Medicine, 2014; 11(4):449-461
Publisher: Future Medicine Ltd
Issue Date: 2014
ISSN: 1741-0541
Statement of
Ashley M Hopkins, Catherine E O'Doherty, David JR Foster, Richard N Upton, Susanna M Proudman, Michael D Wiese
Abstract: Leflunomide is largely considered to be a second-line treatment option for rheumatoid arthritis (RA). Those who fail to respond, tend to progress to treatment with expensive biological agents, which can also be associated with serious toxicities. Optimizing leflunomide treatment to meet the needs of individuals would hence be beneficial in terms of patient outcomes and health care expenditure. In this respect, therapeutic drug monitoring (TDM) may be useful, as plasma concentrations of leflunomide’s active metabolite, teriflunomide, correlate with response to treatment, but are highly variable between patients. A number of pharmacogenetic markers have also been identified that influence response and toxicity. Incorporation of these findings into clinical practice could facilitate more efficient use of leflunomide.
Keywords: Leflunomide; pharmacogenomics; rheumatoid arthritis; teriflunomide; therapeutic drug monitoring
Rights: © 2014 Future Medicine Ltd
RMID: 0030012584
DOI: 10.2217/pme.14.23
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.